New drug combo tested to control advanced breast cancer
NCT ID NCT01872260
Summary
This study is testing two new experimental drugs (LEE011 and BYL719) combined with the standard hormone therapy letrozole for women with advanced ER+ breast cancer. The main goals are to find the safest and most effective doses and to see how well the combinations work to control the cancer. About 255 women who have not had many prior treatments for their advanced cancer will participate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Massachusetts General Hospital SC-5
Boston, Massachusetts, 02114, United States
-
Mays Cancer Ctr Uthsa Mdacc
San Antonio, Texas, 78229, United States
-
Northwest Medical Specialties
Tacoma, Washington, 98405, United States
-
Novartis Investigative Site
Westmead, New South Wales, 2145, Australia
-
Novartis Investigative Site
Parkville, Victoria, 3050, Australia
-
Novartis Investigative Site
Nedlands, Western Australia, 6009, Australia
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Paris, 75475, France
-
Novartis Investigative Site
Saint-Herblain, 44805, France
-
Novartis Investigative Site
Pisa, PI, 56126, Italy
-
Novartis Investigative Site
Seoul, Korea, 03080, South Korea
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28050, Spain
-
Novartis Investigative Site
Seville, 41013, Spain
-
Novartis Investigative Site
Valencia, 46010, Spain
-
Novartis Investigative Site
Bellinzona, 6500, Switzerland
-
Novartis Investigative Site
Glasgow, G12 0YN, United Kingdom
-
Novartis Investigative Site
Manchester, M20 2BX, United Kingdom
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Texas Oncology
Dallas, Texas, 75246, United States
-
UCSF Medical Center
San Francisco, California, 94143, United States
-
Univ of California at San Diego Moores Cancer Ctr
San Diego, California, 92103, United States
-
Vanderbilt University Medical Ctr
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.